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Abstract
Introduction HFE-associated haemochromatosis, the most
common monogenic disorder amongst populations of
northern European ancestry, is characterised by iron
overload. Excess iron is stored in parenchymal tissues,
leading to morbidity and mortality. Population screening
programmes are likely to improve early diagnosis, thereby
decreasing associated disease. Our aim was to develop and
validate a health economics model of screening using
utilities and costs from a haemochromatosis cohort.
Methods A state-transition model was developed with
Markov states based on disease severity. Australian males
(aged 30 years) and females (aged 45 years) of northern
European ancestry were the target populations. The
screening strategy was the status quo approach in Aus-
tralia; the model was run over a lifetime horizon. Costs
were estimated from the government perspective and
reported in 2015 Australian dollars ($A); costs and quality-
adjusted life-years (QALYs) were discounted at 5%
annually. Model validity was assessed using goodness-of-
fit analyses. Second-order Monte-Carlo simulation was
used to account for uncertainty in multiple parameters.
Results For validity, the model reproduced mortality, life
expectancy (LE) and prevalence rates in line with pub-
lished data. LE for C282Y homozygote males and females
were 49.9 and 40.2 years, respectively, slightly lower than
population rates. Mean (95% confidence interval) QALYS
were 15.7 (7.7–23.7) for males and 14.4 (6.7–22.1) for
females. Mean discounted lifetime costs for C282Y
homozygotes were $A22,737 (3670–85,793) for males and
$A13,840 (1335–67,377) for females. Sensitivity analyses
revealed discount rates and prevalence had the greatest
impacts on outcomes.
Conclusion We have developed a transparent, validated
health economics model of C282Y homozygote
haemochromatosis. The model will be useful to decision
makers to identify cost-effective screening strategies.
Key Points for Decision Makers
This is the first validated economic model to be
published for C282Y homozygote
haemochromatosis for the Australian setting utilising
utilities and costs from a haemochromatosis cohort.
From the government perspective, mean discounted
lifetime direct medical costs for C282Y homozygote
males were estimated to be more than 1.5 times that
of females ($A22,737 vs. $A13,840).
The model estimated mean discounted quality-
adjusted life-years associated with the current
screening approach were 15.654 for males and
14.390 for females.
This model can be used by decision makers to
identify cost-effective screening and treatment
strategies for C282Y homozygote
haemochromatosis.
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1 Introduction
HFE-associated hereditary haemochromatosis is the most
common monogenic disorder amongst populations of
northern European ancestry [1–3]. Whilst several mutations
of the HFE gene have been identified, C282Y homozygotes
account for between 80 and 90% of the burden of disease
[4, 5]. The prevalence of this genotype has been estimated to
be between 1 in 150 and 1 in 200 in populations of northern
European ancestry (i.e. UK, Ireland and Scandinavian
countries) [6–9]. Prevalence in populations of other ances-
tries is far lower, with estimates in the range of 1 in 1000 for
both First Nation and African Americans [10] and 1 in
1 million amongst Asian populations [11].
Clinically, haemochromatosis is characterised by iron
overload, with excess iron stored in the parenchymal tis-
sues of the liver, heart and pancreas [2, 12, 13]. Early
symptoms of iron overload are non-specific, including
fatigue, lethargy and arthropathy of the metacarpopha-
langeal joints. As iron overload progresses, liver disease,
heart disease and type 2 diabetes mellitus can occur.
Clinical penetrance is incomplete: a further genetic muta-
tion is thought to play a role in this process [14, 15]. Whilst
age of onset of iron overload varies, males typically
develop overload at an earlier age as menstruation assists in
reducing iron stores in females [6].
Both diagnosis and treatment of haemochromatosis are
straightforward. The former involves iron studies, most
importantly transferrin saturation (TfS) and ferritin, with
confirmatory HFE genotyping. Treatment involves regular
therapeutic venesection. When treatment is commenced
prior to organ damage and maintained, the patient will not
experience any long-term health problems related to
haemochromatosis and retains normal life expectancy
(LE). However, as the early symptoms of haemochro-
matosis are non-specific, timely diagnosis is often missed
until organ damage has occurred [16, 17]. In order to
increase early diagnosis, population screening programmes
have been suggested [18–21].
Screening programmes are typically resource intensive,
and therefore decision makers need to be confident that
such interventions are likely to be cost effective prior to
their introduction. Economic modelling is a method that
assists decision makers to evaluate the cost effectiveness of
a given intervention [22]. Long-term costs and conse-
quences of the disorder with or without screening can be
predicted by using existing clinical, epidemiological and
cost data combined in a suitable model. However, to date,
no health economic model based on costs and utilities from
a haemochromatosis cohort has been published. To address
this lack of evidence, we have developed a model to assess
screening strategies for the Australian setting for people
homozygous for the C282Y mutation. The aim of this
paper is to describe the construction and validation of our
haemochromatosis screening model and to present model
predictions for LE, quality-adjusted life-years (QALYs)
and total lifetime costs associated with haemochromatosis.
2 Methods
2.1 Model Structure
We constructed a cost-effectiveness model using a Markov
approach allowing for modelling of multiple disease states
over a lifetime horizon. The cycle length was 1 year, which
continued to run until the death of all simulated subjects. A
lifetime horizon was selected to reflect the chronic nature
of haemochromatosis. The perspective taken was that of
the government. This perspective was adopted as funding
decisions are based, in part, on these government costs.
Both costs and effectiveness were discounted annually by
5%, in line with the Australian guidelines [23]. The
structure of the model is detailed in ‘‘Appendix 1’’. The
model was constructed using TreeAge Pro Suite 2014
(TreeAge Software, Williamstown, MA, USA). Validation
was conducted using TreeAge Pro and SPSS version
22.0.0.0 (IBM Corp., Armonk, NY, USA). Modelled output
data were exported into SPSS allowing for calculation of
correlation coefficients and fitting linear curves for good-
ness-of-fit analyses.
Markov states were categorised according to the Euro-
pean Association for the Study of the Liver’s (EASL)
recommendations pertaining to how research on
haemochromatosis is reported (Table 1) [18]. The four
categories represent increasing severity of haemochro-
matosis and iron overload. For the Markov model, an
absorbing ‘Death’ state was also included. Figure 1a, b
provide an overview of the possible transitions between
these states (‘‘Appendix 1’’ provides a more detailed
flowchart showing the steps in the screening process).
Simulated participants could move in either direction
between the four categories of haemochromatosis for all
Table 1 Categories of haemochromatosis [17]
Category
1
Genetic mutation only (C282Y homozygotes, H63D
heterozygotes and compound heterozygotes)
Category
2
Genetic mutation and elevated iron studies, either
transferrin saturation or serum iron
Category
3
Genetic mutation, elevated iron levels and early
symptoms (e.g. arthritis, fatigue, lethargy)
Category
4
Genetic mutation, elevated iron levels and organ damage
(e.g. liver cirrhosis, hepatocellular carcinoma, heart
disease, type 2 diabetes mellitus)
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disease states except Category 4, as this included irre-
versible organ damage, and could also move to the
absorbing state of ‘Death’. Clinical pathways that were
incorporated into the model (screening, diagnosis and
treatment) were based on current guidelines and input from
an expert clinician (KCY). The model structure was
designed by a health economist/clinician (AJP) and three
health economists (BdG, LS, ALN).
Probabilities were calculated for each possible transition
through the model, as outlined in Fig. 1. These annual
probabilities were calculated based on data from an epi-
demiological study [6] (Table 2). Transition probabilities
were mediated by adherence to treatment, i.e. non-adher-
ence led to a higher probability of a participant moving to a
more severe category of haemochromatosis. Transition
probabilities for the ‘Death’ state were set at age- and sex-
specific mortality rates for the Australian population [24]
for all states with the exception of Category 4. As Cate-
gory 4 is characterised by irreversible organ damage, a
higher probability of death was assumed, as discussed in
Sect. 2.1.5.
2.1.1 Base-Case Populations
Two base-case populations were selected for analysis:
males 30 years of age and females 45 years of age, both of
northern European ancestry. The rationale for this decision
was based on prevalence and penetrance estimates.
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Fig. 1 a Overview of model structure. b Transitions from haemochromatosis categories based on adherence to treatment. HMZ homozygote,
?ve positive, –ve negative
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Table 2 Key model parameters
Parameter Base case Range for SA Distribution Source
Males Females Males Females
Prevalence of C282Y homozygotesa 0.0068 0.0068 0.0044–0.0074 0.0044–0.0074 Triangular [6, 8, 9, 18]
Probabilities for categories of haemochromatosis
Category 1 0.8 0.95 0.64–0.096b 0.76–1.00b Triangular [9, 18]
Category 2 0.2 0.05 0.16–0.24b 0.04–0.06b Triangular
Category 3 0 0
Category 4 0 0
Annual transition probabilities [9, 54]
With treatment
Category 1 to 2 0 0
Category 2 to 1 1–(mortalityc) 1–(mortalityc)
Category 2 to 3 0 0
Category 3 to 2 0.0083 0.0083 0.0064–0.0096b 0.0064–0.0096b Triangular
Category 3 to 4 0 0
Category 4 to die 0.0167 0.0167 0.0134–0.0200a 0.0134–0.0200a Triangular
Without screening and/or treatment
Category 1 to 2 0.071 0.0542 0.0568–0.0852b 0.04336–0.0650b Triangular
Category 2 to 1 0 0
Category 2 to 3 0.0625 0.0167 0.050–0.075b 0.0134–0.0200b Triangular
Category 3 to 4 0.0083 0.0083 0.0064–0.0096b 0.0064–0.0096b Triangular
Category 4 to die 0.0167 0.0167 0.0134–0.0200b 0.0134–0.0200b Triangular
Adherence to therapeutic venesection (3–4 times annually)
Year 1 0.905 0.724–1.000b Triangular [30]
Year 2 0.837 0.670–1.000b Triangular
Year 3 0.769 0.615–0.923b Triangular
Year 4 0.701 0.561–0.841b Triangular
Year 5 0.633 0.506–0.760b Triangular
Year 6 0.565 0.452–0.678b Triangular
Year 7 0.497 0.398–0.596b Triangular
Year 8 0.429 0.343–0.515b Triangular
Year 9 0.361 0.289–0.433b Triangular
Year 10 and thereafter 0.293 0.234–0.352b Triangular
Government costs incurred in categories of haemochromatosisd
Category 1 824 434–1213b Log-normal [34]
Category 2 1949 1162–3018b Log-normal
Category 3 3681 2945–4417b Log-normal
Category 4 10,393 8313–12,472b Log-normal
Unit costs of screening strategy elementsd
GP Level A 16.95 n/a* Log-normal [33, 55]
GP Level B 37.05 n/a* Log-normal
Iron studies 27.70 n/a* Log-normal
HFE genotype: blood 31.00 n/a* Log-normal
Initial medical specialist appointment 72.75 n/a* Log-normal
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Northern European ancestry was chosen as the prevalence
of C282Y homozygosity is far higher than reported for
populations of other ancestries [6, 10]. Amongst males,
iron overload and related complications typically occur
from the age of 30 years onwards, and this has been the
preferred age in other haemochromatosis models [25–27].
The second base-case population consisted of females
45 years of age, as females tend to experience iron over-
load following commencement of menopause [28].
2.1.2 Screening
A single screening strategy was modelled for validation
purposes, which was based on the status quo approach in
Australia. Screening was assumed to occur at age 30 years
for males and 45 years for females. Screening occurs either
through a cascade approach, in which first-degree relatives
of a homozygote are offered genotyping, and iron studies
reimbursed by the Medical Benefits Scheme (MBS).
Alternatively, screening occurs incidentally, consisting of a
three-step process: two consecutive elevated TfS tests
followed by HFE genotyping. In our model, when a par-
ticipant tested negative to the genotype test, a referral to a
specialist medical practitioner for further investigation was
assumed (‘‘Appendix 1’’). Genetic counselling was
assumed to take place during the medical consultations
conducted before and after HFE genotyping. At present,
this combined approach is estimated to diagnose 31% of
C282Y homozygotes in Australia (L. Gurrin, Principal
Investigator, HealthIron study, personal communication,
16 March 2015).
As no data were available to inform uptake of cascade
and incidental screening in Australia, expert opinion and
literature were relied on to inform this. The uptake rate for
any screening for a population of northern European
ancestry was estimated to be 5% [29]. This group was then
Table 2 continued
Parameter Base case Range for SA Distribution Source
Males Females Males Females
Sensitivity
HFE genotype 0.92 0.92 0.736–1.00b 0.736–1.00b Triangular Genotype [41];
transferrin
saturation [42]
First transferrin saturation 0.938 0.546 0.750–1.00b 0.437–0.655b Triangular
Second transferrin saturation 0.90 0.55 0.72–1.00b 0.44–0.66b Triangular
Specificity
HFE genotype 0.994 0.994 0.795–1.00b 0.795–1.00b Triangular
First transferrin saturation 0.981 0.981 0.785–1.00b 0.785–1.00b Triangular
Second transferrin saturation 0.996 0.994 0.797–1.00b 0.795–1.00b Triangular
Uptake of screening
Populationa 0.05 0.025–0.075e Triangular Estimatesf
Of these:
Cascade screening 0.50 Triangular
Incidental screening 0.50 Triangular
Utilities
Category 1 0.88 0.71 0.70–1.00b 0.57–0.85b Beta [38]
Category 2 0.85 0.77 0.68–1.00b 0.62–0.92b Beta
Category 3 0.59 0.60 0.47–0.71b 0.48–0.72b Beta
Category 4 0.59 0.41 0.47–0.71b 0.33–0.49b Beta
Annual discount rate
Costs 0.05 0.00–0.07 [23]
Effectiveness 0.05 0.00–0.07
GP general practitioner, HFE the gene largely responsible for haemochromatosis, n/a not applicable, SA sensitivity analysis
* SA was carried out on total screening costs, not unit costs
a This refers to persons of northern European ancestry
b One-way SA values ±20% of base-case value
c Mortality rates used were age and sex specific, and obtained from the Australian Bureau of Statistics [24]
d All costs are in 2015 Australian dollars
e One-way SA values ±50% of base-case value
f These estimates were based on expert opinion as no data were available
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equally divided as to whether they were screened via a
cascade or incidental approach.
Estimates for adherence to treatment were taken from a
longitudinal study describing this over a 9-year period [30].
Based on this study, patient adherence was set at 90.5% in
year 1, decreasing linearly to 29.3% in year 9. For the
purposes of the model, the estimate of adherence plateaued
at 29.3% from year 10 onwards. Adverse events associated
with treatment were not included in the model as vene-
section is considered a safe treatment, with adverse events
typically limited to dizziness and/or syncope subsequent to
treatment [30, 31]. In Australia, the clinician providing
venesection typically provides care to the patient.
2.1.3 Costs
Costs were reported from the government perspective, and
were limited to direct medical costs, although other costs
(indirect and direct non-medical costs) can also be included
in the model. The costs were screening and state (category)
costs, both of which were reported in 2015 Australian
dollars ($A) (0.75 US dollars). Costs were deflated to
constant prices using the price index for Government final
consumption expenditure on hospitals and nursing homes
for 2013/2014 [32].
Direct medical costs associated with screening were
sourced from the 2015 MBS [33]. Specific costs related to
genetic counselling were not included, as this was assumed
to be provided by the medical practitioner during the
consultations conducted before and after HFE genotyping.
Costs were based on the assumption that repeat testing,
related to either collection or analysis errors, was not
required.
The costs associated with haemochromatosis states were
sourced from our previous cost-of-illness study [34]. This
study estimated the costs of haemochromatosis on the basis
of a national survey using a bottom-up approach. To date,
these are the only published cost estimates for
haemochromatosis. Costs were reported for each of the
four EASL categories of haemochromatosis and are defined
in Table 2. These costs were used for hypothetical partic-
ipants who were diagnosed and received treatment. For
participants either not diagnosed or not adhering to treat-
ment, treatment costs, i.e. therapeutic venesection, were
subtracted from the total costs for each category. Further,
costs for undiagnosed Category 1 patients (either not
screened or a false-negative test) were set a zero. A brief
description of the costing methodology is included here,
but readers are directed to the original paper for a more
detailed description [34].
Costs included were limited to resources funded by
federal or state and territory governments. Pharmaceutical
costs were based on the subsidy from the 2015
Pharmaceutical Benefits Scheme (PBS) Price Schedule of
1 January 2015 [35]—the difference between the dispensed
price and the co-payment, if the dispensed price is greater.
Unit costs for medical consultations and investigations
(blood tests, liver biopsies, X-rays, etc.) were derived from
the Medicare Benefits Schedule Book [33]. The National
Hospital Cost Data Collection cost weights for Australian
Refined Diagnosis-Related Group (AR-DRG) version
6.0 9 (2011–2012) were used to estimate public hospital
events [36]. Costs for public outpatient admissions were
costed as reported by the Independent Hospital Pricing
Authority [37].
2.1.4 Effectiveness
Health state utility values (HSUVs) were used to calculate
QALYs. Utility values were taken from a recently pub-
lished study by our group, the only study to date that has
assessed utility values directly in people with haemochro-
matosis [38]. This study reported HSUVs amongst a sam-
ple of Australian adults with haemochromatosis, using the
Assessment of Quality of Life 4D (AQOL-4D) instrument
[38]. Mean utilities and their distributions were calculated
for each of the four EASL categories (Tables 1, 2).
2.1.5 Mortality
Mortality associated with haemochromatosis was assumed
to be the same as the Australian population age- and sex-
adjusted rates, with the exception of Category 4. Age- and
sex-adjusted mortality was sourced from Australian life
tables [24], which are based on demographic data collected
by the Australian Government for the entire population
(Table 2). For Category 4, as irreversible organ damage
(e.g., liver cirrhosis, heart disease) characterises this cate-
gory, an elevated probability of death was assigned to this
state reflecting current literature. A multiplier of 2.45 (95%
confidence interval [CI] 2.27–2.64) was applied to the age-
and sex-specific mortality rates for the Australian popula-
tion, based on an estimate from an epidemiological study
[39].
2.1.6 Bayes’ Revision
As with almost all diagnostic tests, the sensitivity and
specificity of TfS and HFE genotyping as diagnostic tools
for haemochromatosis are imperfect, i.e. both less than
100%. To address this, the Bayes’ revision function within
the TreeAge model structure was used. This function,
based on Bayes’ theorem [40], combines prior and poste-
rior probabilities (or, alternatively, combines a prior odds
with a likelihood ratio to generate a posterior odds for a
given hypothesis) as per the following formula (Eq. 1):
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PðHypothesisjEvidenceÞ
¼ PðEvidencejHypothesisÞ  PðHypothesisÞ
PðEvidenceÞ
ð1Þ
where P(Hypothesis) is the prior probability of the
hypothesis of disease (usually taken to be the unadjusted
population prevalence if we are considering a diagnostic
test for a binary outcome) and P(Evidence) is the marginal
probability of the evidence given that the hypothesis is
true, usually derived from a ‘sampling model’ for the
probability of the observed data given values of the sen-
sitivity and specificity consistent with the hypothesis. The
model incorporated four posterior probabilities in both the
incidental and cascade screening sub-branches, specific to
the tests ordered. The estimates of sensitivity and speci-
ficity for genotyping [41] and TfS tests [42] are displayed
in Table 2.
2.2 Sensitivity Analyses
Probabilistic decision analysis with simultaneous sampling
from distributions of key input parameters was used to
address uncertainty. Tornado diagrams were produced for
both populations to identify parameters with the greatest
individual impact on costs and effectiveness. Prevalence of
C282Y homozygosity, adherence to treatment, transition
probabilities, Category 4 mortality rates, utility values and
costs were varied by ±20% of the values used in the base-
case analysis [43]. Screening uptake was varied by ±50%
of the values used in the base-case analysis, reflecting the
greater uncertainty given reliance on expert opinion. Dis-
counting of both costs and effectiveness was varied
between zero and 7%, from the base-case of 5%. Based on
these results, one-way sensitivity analysis of all key input
parameters was performed. For variables that were defined
by a distribution, probabilistic sensitivity analysis was
conducted to incorporate multiple parameter uncertainties
simultaneously.
2.3 Model Validity
Validation of the model followed the recommendations of
the International Society of Pharmacoeconomics and Out-
comes Research (ISPOR) Task Force-7 [44]. Face and
internal validity were addressed; however, as no long-term
data were identified that could be used to assess external
validity, this was not conducted. Face validity is a sub-
jective approach involving people with clinical expertise in
the disease area, thus ensuring the model incorporates the
highest level of clinical evidence. The overall structure of
Table 3 Internal validity from model predictions
Parameters Annual mortality rate from
model predictions
Annual mortality rate from
literature [24]
Mortality rates for males at ages (years)
30 0.00079 0.00079
40 0.00134 0.00134
50 0.00291 0.00291
60 0.00678 0.00678
70 0.01690 0.01691
80 0.05126 0.05126
Mortality rates for females at ages (years)
45 0.00121 0.00121
55 0.00270 0.00270
65 0.00626 0.00626
75 0.01783 0.01783
85 0.06603 0.06603
Model predictions Data from literature
Life expectancy (years)
Male aged 30 51.0 51.0 [24]
Female aged 45 40.4 40.4 [24]
Prevalence of C282Y homozygotes amongst persons of northern European ancestrya (%)
Males 0.62 (0.0006) 0.75 [42]; 0.68 [6]; 0.44 [10]
Females 0.62 (0.0006)
a Whilst the prevalence of C282Y homozygosity is the same for both sexes, the model was run separately for males and females. As a result, they
are reported separately
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the model, population, screening approaches, outcomes and
assumptions were reviewed and validated by a hepatologist
(KCY), biostatistician (LCG) and four health economists
(AJP, LS, BdG, ALN).
Internal validity involved assessments to ensure the
correct mathematical calculations were implemented. This
was conducted by validating equations and parameters
against their sources (BdG, LS). Modelled mortality rates,
LE and prevalence for C282Y homozygosity for males and
females at various ages were compared with the mortality
data that were used to populate the model [24] and
prevalence estimates [10, 42, 45]. One-way sensitivity
analyses were conducted, as previously discussed, to
ensure the results changed as expected when input
parameter values were varied.
3 Results
3.1 Results of Validity Assessment
3.1.1 Face Validity and Internal Validation
For face validity, the model structure was found to rep-
resent all clinical aspects of haemochromatosis correctly
[7, 17, 46, 47]. To assess internal validity, mortality rates
and LE generated by the model were compared with the
published rates used to build the model (Table 3) [24].
The modelled predictions for mortality rates for males
(at ages 30, 40, 50, 60, 70 and 80 years) and females (at
ages 45, 55, 65, 75 and 85 years) were plotted against the
published rates and the goodness of fit for the linear
relationship assessed (Fig. 2a). The correlation coeffi-
cient (R2) was 1.00, indicating the model accurately
reproduced the inputted mortality rates. Similarly, for
the overall cohort, the model predicted LE of 30-year-
old males to be 51.0 years, identical to the data reported
in the Australian Bureau of Statistics’ (ABS) Life
Tables (51.0 years) (Table 3) [24]. For females aged
45 years, the model predicted LE of 40.4 years, consis-
tent with the data from the ABS Life Tables (40.4 -
years). These findings were as expected, given the
relatively low prevalence of C282Y homozygotes. Fur-
ther, the penetrance of Category 4—the only state with
elevated mortality rates—is very low, ranging between 0
and 0.01% (Fig. 4a, b). R2 was 1.00, indicating the
model accurately calculated LE (Fig. 2b). The model
also predicted prevalence of C282Y homozygosity for
male and female cohorts (Table 3). The model predicted
a prevalence rate of 0.62%, similar to the rate reported
from a large prevalence study of northern Europeans
(0.75%) [42], and R2 was 0.905.
3.2 Model Predictions
Table 4 displays the results of the base-case Monte-Carlo
simulations, calculated from age 30 years for males and
45 years for females. LE was estimated specifically for
C282Y homozygotes: for 30-year-old males, LE (standard
deviation) was estimated to be 49.9 years (0.04), 1.1 years
less than the Australian LE for 30-year-old males
(51.0 years). The projected LE for female C282Y
homozygotes aged 45 years was 40.2 years (0.01),
0.3 years less than the Australian LE for females of the
same age (40.4 years). The mean (95% CI) discounted
QALYs associated with screening were 15.7 (7.7–23.7) for
males and 14.4 (6.7–22.1) for females. Figure 3a, b illus-
trate the dispersion of the cost and effectiveness results in
scatterplots. The model also predicted mean lifetime direct
medical costs (95% CI) for male C282Y homozygotes as
$A22,737 (3670–85,793) and $A13,840 (1335–67,377) for
females.
3.3 Time in States
The model projected the time spent in each disease state
(Table 4). The low rates of uptake of screening and
adherence to treatment were the drivers of transition to
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Categories 3 and 4, the states in which co-morbidities
related to iron overload occur. Males spent a mean of
23 years in Category 3 and 3 years in Category 4, whilst
females, with lower clinical penetrance, spent a projected
mean of 6 years in Category 3 and less than 1 year in
Category 4.
The model predicted the probabilities of both the male
and female cohorts being in each of the five Markov states
for each stage of the model, until all hypothetical partici-
pants were in the absorbing ‘Death’ state (Fig. 4a, b). For
both sexes, the probability of being in Category 1 increased
between the first two stages, and, conversely, the proba-
bility of being in Category 2 decreased. This result is a
function of screening, in that 90.5% of Category 2 patients
access treatment subsequent to screening. Therefore, most
Category 2 participants transition to Category 1, the
impacts of haemochromatosis being potentially reversible
until Category 4. This effect is less dramatic for females as
fewer females than males are in Category 2 at the time of
screening (80 and 95%, respectively).
For both sexes, the probability of being in Category 1
decreased over time, reflecting reduced adherence to
treatment: from 90.5% in the first year to 29.3% in the tenth
year and thereafter [30]. In turn, the probability of being in
Categories 2, 3 or 4 increased. Participants in Category 4
had a higher probability of moving into the ‘Death’ state
than other participants. In addition, the probability of
transitioning into the ‘Death’ state increased with the
advancing age of the cohort, in line with population data
[24].
3.4 Sensitivity Analysis
One-way sensitivity analyses were carried out by varying
the value by ±20% for all key parameters, with the
exception of uptake of screening (±50%) and discounting
(varied between 0 and 7%) (‘‘Appendix 2’’). Tornado
diagrams were constructed to identify parameters with the
greatest effect on costs and effectiveness. The five
parameters with the greatest impact (discount rate, preva-
lence, probability of starting in Category 1, transition from
Category 1 to 2 and costs associated with Categories 2 and
3) are included in ‘‘Appendix 2’’.
For males, varying the discount rate had the most
notable effect on both costs and effectiveness. With no
discounting, mean costs increased from the base-case
estimate of $A145 to $A497 and effectiveness increased
from 15.7 to 42.2 QALYs. When the discount rate was set
at 7%, mean costs decreased to $A101 and effectiveness
reduced to 11.9 QALYs. Varying the prevalence also had
an impact on costs: increasing the estimate by 20%
increased mean costs to $A185, and decreasing the
Table 4 Results of base-case analyses
Males (age 30 years) (SD) Females (age 45 years) (SD)
LE (C282Y homozygotes) 49.9 (0.04) 40.2 (0.01)
Populationa C282Y homozygotes
Costs (2015 $A) Effectiveness (QALYs) Costs (2015 $A) LE (years)
Males
Mean 145 15.654 22,737 49.91
Standard deviation 148 4.062 25,104 0.04
95% CI 29–498 7.694–23.668 3670–85,793 –
Females
Mean 91 14.390 13,840 40.15
Standard deviation 135 3.955 22,696 0.01
95% CI 15–414 6.660–22.142 1335–67,377 –
Time (years) in disease states C282Y homozygotes
Males (SD) Females (SD)
Category 1 10.42 (0.00) 14.77 (0.00)
Category 2 13.53 (0.00) 19.54 (0.00)
Category 3 23.19 (0.00) 5.51 (0.00)
Category 4 2.79 (0.04) 0.41 (0.01)
$A Australian dollars, CI confidence interval, LE life expectancy, QALYs quality-adjusted life-years, SD standard deviation
a Population refers to the entire hypothetical cohort of males or females of northern European ancestry
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estimated by 20% reduced costs to $A126. Varying uptake
of screening (±50%) marginally impacted costs and
effectiveness. Decreasing uptake reduced costs to $A143,
and increasing uptake increased costs to $A146. No
notable impact on effectiveness was observed (\0.001
QALY). Varying the mortality multiplier had negligible
effects on cost and effectiveness for males (\$A1
and\ 0.001 QALY, respectively). For LE, varying the
multiplier for mortality by ±20% (1.96–2.94) resulted in
small changes. For males aged 30 years, decreasing the
multiplier increased LE to 50.2 years from a base-case LE
estimate of 40.1 years, and, conversely, increasing the
multiplier decreased LE to 49.7 years. One-way sensitivity
analysis on other variables showed small impacts on costs
and effectiveness (‘‘Appendix 2’’).
For females, the parameter with the most effect on costs
and effectiveness was the discount rate. Decreasing this to
zero resulted in costs increasing to $A264 from the base-
case estimate of $A91, and increasing this rate to 7%
decreased costs to $A64. Similarly, effectiveness increased
from the base-case estimate of 14.4 to 33.1 QALYs gained
with no discounting and decreased to 11.3 QALYs gained
when the discount rate was set at 7%. Increasing the
prevalence estimate increased costs to $A114; when this
was decreased, costs reduced to $A79. Decreasing the
uptake estimate by 50% reduced costs to $A89, and
increasing this estimate increased costs to $A93. No
notable change in effectiveness was observed (\ 0.001
QALY). Similar to males, varying the mortality multiplier
had negligible effects on costs and effectiveness (\$A1
and\0.001 QALY gained, respectively). The LE of
females aged 45 years increased by\0.01 years when the
multiplier was decreased by 20% (40.2 years), and, con-
versely, LE decreased to 40.1 years when the multiplier
was increased. All other sensitivity analyses revealed
minor changes from the base-case estimate (‘‘Appendix
2’’).
4 Discussion
This is the first economic model to be published using
utility and cost data from a haemochromatosis cohort to
populate a Markov model with probabilistic decision
analysis—the approach best suited to this chronic, pro-
gressive disease. Just one other model has evaluated the
cost effectiveness of population screening for haemochro-
matosis, using a Markov model with probabilistic decision
analysis [25]. Our model has built on this previously
published model by incorporating multiple disease states as
recommended by the EASL, along with disease-specific
cost and utility data derived from people living with
haemochromatosis. Previous models used estimates of
costs and utilities based on expert opinion [5, 26, 48, 49].
The number of health technology assessments being
conducted has increased over the past two decades and,
with an increasing focus on value in healthcare, this is
likely to continue. Whilst clinical studies are ideally placed
to assess the short- to medium-term costs and effectiveness
of interventions, long-term costs and effectiveness are most
feasibly and efficiently assessed through modelling.
Important considerations for modelling studies include use
of the highest quality clinical and epidemiological data
available, transparency, and acceptability to patient groups,
expert clinicians, decision makers and healthcare payers.
The model for haemochromatosis that we have constructed
has aimed to address all of these issues.
The model was assessed for internal validity using linear
regression. The R2 values of the slopes indicated the
modelled projections closely correlated with the inputted
and external data. All key input parameters, results of one-
way sensitivity analyses and the structure of the model
have been provided to enhance transparency. A limitation
of this study was that external validation of the model was
not conducted. To date, limited data on the long-term
clinical and health economic outcomes of haemochro-
matosis have been published. As a result, where these data
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Fig. 3 Cost-effectiveness scatterplot for the status quo strategy for
males (a) and females (b). $A Australian dollars, QALYs quality-
adjusted life-years
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were available, they were used in the construction of the
model, thereby rendering external validation not possible.
The base-case analyses estimated the mean direct
medical costs associated with screening and consequential
treatment for those identified was $A145 for males and
$A91 for females. The higher costs incurred by males
than females are expected given the higher rate of clinical
penetrance for males. One-way sensitivity analysis iden-
tified no parameters which altered this. Increasing the
penetrance for females by increasing the probability of
commencing in Category 2 (rather than Category 1) had a
negligible effect on costs and effectiveness in comparison
to the base-case results. Another factor contributing to the
lower costs for females is the low sensitivity of TfS as a
screening test for females. This results in missed diag-
noses and lower total screening costs (two consecutive
elevated TfS tests followed by confirmatory genotype) as
fewer females than males will go on to have the second
TfS test and genotype. In turn, potential venesection
treatment costs are not accrued. Whilst in our model
female C282Y homozygotes who are not diagnosed, and
therefore not receiving treatment, still accrue costs (with
the exception of Category 1), these costs are smaller as
venesection costs are excluded. Further, treatment costs
accrue in the future, and are thus subject to discounting.
Overall, the trade-off for this lower cost screening strat-
egy is the reduced identification of female homozygotes.
The trade-off between any cost savings versus the greater
burden of disease generated is an issue that requires
careful consideration.
Our model, consistent with other published studies,
reported relatively high levels of uncertainty as evidenced
by large standard deviations and 95% CIs reported in the
base-case analyses [4, 25, 41, 50, 51]. However, these
uncertainties were addressed in our one-way sensitivity
analyses and, with the exception of discounting, were
found to have little impact on the base-case results. Our
primary avenue to minimise uncertainty was by utilising
patient-derived information on costs and utilities associated
with EASL categorisations.
One-way sensitivity analyses were conducted by vary-
ing the base parameter values by ±20%, with the exception
of uptake of screening (±50%). For these parameters, the
95% CIs were within the ±20% ranges adopted. Whilst
conducting one-way sensitivity analyses by varying the
base parameter values by ±20% is an approach
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recommended by ISPOR [44], using the 95% CIs for each
parameter represents an alternative, useful approach.
Projected LE for C282Y homozygotes was marginally
lower than for the general population. The mortality mul-
tiplier applied to Category 4 of 2.45 [39] was in-line with
other recent epidemiological work on mortality associated
with haemochromatosis [52]. Whilst higher mortality rates
were adopted for Category 4, the low penetrance rate for
this category resulted in marginal impacts on overall
mortality in both the base-case and sensitivity analyses.
Our model has been developed to allow for comparisons
between the status quo approach of screening for
haemochromatosis and alternatives, such as population-
level genetic or neonatal screening [53]. Our model is well-
placed to assist decision makers in Australia to assess
different screening strategies for haemochromatosis. Fur-
ther, it is flexible enough that alternative parameters may
be used to allow for cost-effectiveness analyses in different
jurisdictions.
5 Conclusion
A transparent and validated health economics model of
screening for C282Y homozygote haemochromatosis based
on Australian economic, epidemiological and clinical data
has been developed. The model will be useful to decision
makers to identify cost-effective screening and treatment
strategies for C282Y homozygote haemochromatosis.
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